文献速递产科母胎医学

游离DNA生物标志物与患者数据在子痫前期早期预测中的作用:人工智能模型

The role of cell-free DNA biomarkers and patient data in the early prediction of preeclampsia: an artificial intelligence model.
PubMed 文献 · Am J Obstet Gynecol · 2024-03-02

该研究为前瞻性多中心观察性产前游离DNA筛查研究(SMART)的二次分析,纳入17,520例单胎妊娠,利用首次产检常规收集的13项患者特征及2项游离DNA特征(总游离DNA和胎儿分数)构建逻辑回归与神经网络模型预测早发型、早产及足月子痫前期。结果显示,子痫前期与较高的总游离DNA和较低的胎儿分数相关,神经网络与逻辑回归模型性能相似,总游离DNA和胎儿分数对足月及早产子痫前期预测贡献可忽略。

要点

  • 在15%筛查阳性率下,早产子痫前期灵敏度逻辑回归模型为58.4%,神经网络模型为59.3%。
  • 子痫前期孕妇总游离DNA中位数362.3 copies/mL高于非子痫前期339.0 copies/mL,胎儿分数中位数7.5%低于9.4%。
  • 早发型子痫前期预测中,神经网络模型移除总游离DNA和胎儿分数特征后,15%筛查阳性率下灵敏度从54.9%降至48.0%。

核心结论

  • 常规可用的患者特征和游离DNA标志物可用于预测子痫前期,其预测早产子痫前期的性能与其他患者特征模型相当。
  • 逻辑回归与神经网络模型表现出相似的预测性能。

研究设计与样本

  • 本研究为前瞻性、多中心、观察性产前游离DNA筛查研究(SMART)的二次分析,纳入单胎妊娠且妊娠结局已知的孕妇。
  • 最终分析共纳入17,520例参与者,使用首次产检常规收集的13项患者特征和2项游离DNA特征(总游离DNA和胎儿分数)构建预测模型。
  • 参考分类器为浅层逻辑回归模型,并探索了至少1个隐藏层的前馈神经网络架构,最终选用含1个隐藏层、15个单元的简单神经网络模型。

主要发现

  • 在17,520例参与者中,72例(0.4%)发生早发型子痫前期,251例(1.4%)发生早产子痫前期,420例(2.4%)发生足月子痫前期。
  • 游离DNA检测孕周中位数为12.6周,2155例(12.3%)在≥16周时进行检测。
  • 子痫前期与较高的总游离DNA相关(中位数362.3 vs 339.0 copies/mL,P<.001),与较低的胎儿分数相关(中位数7.5% vs 9.4%,P<.001)。
  • 早发型、早产和足月子痫前期的交叉验证曲线下面积:逻辑回归模型分别为0.782、0.801和0.712;神经网络模型分别为0.797、0.800和0.713。
  • 在15%筛查阳性率下,早产子痫前期灵敏度逻辑回归模型为58.4%(95%CI 0.569-0.599),神经网络模型为59.3%(95%CI 0.578-0.608);总游离DNA和胎儿分数对足月及早产子痫前期预测贡献可忽略;早发型子痫前期中,神经网络模型移除总游离DNA和胎儿分数特征后,15%筛查阳性率下灵敏度下降6.9%,从54.9%(95%CI 52.9-56.9)降至48.0%(95%CI 45.0-51.0)。

临床怎么用

  • 原文未据此给出推荐,仅指出常规可用的患者特征和游离DNA标志物可用于预测子痫前期,且逻辑回归与神经网络模型性能相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accurate individualized assessment of preeclampsia risk enables the identification of patients most likely to benefit from initiation of low-dose aspirin at 12 to 16 weeks of gestation when there is evidence for its effectiveness, and enables the guidance of appropriate pregnancy care pathways and surveillance. OBJECTIVE: The primary objective of this study was to evaluate the performance of artificial neural network models for the prediction of preterm preeclampsia (<37 weeks' gestation) using patient characteristics available at the first antenatal visit and data from prenatal cell-free DNA screening. Secondary outcomes were prediction of early-onset preeclampsia (<34 weeks' gestation) and term preeclampsia (≥37 weeks' gestation). METHODS: This secondary analysis of a prospective, multicenter, observational prenatal cell-free DNA screening study (SMART) included singleton pregnancies with known pregnancy outcomes. Thirteen patient characteristics that are routinely collected at the first prenatal visit and 2 characteristics of cell-free DNA (total cell-free DNA and fetal fraction) were used to develop predictive models for early-onset (<34 weeks), preterm (<37 weeks), and term (≥37 weeks) preeclampsia. For the models, the "reference" classifier was a shallow logistic regression model. We also explored several feedforward (nonlinear) neural network architectures with ≥1 hidden layers, and compared their performance with the logistic regression model. We selected a simple neural network model built with 1 hidden layer and made up of 15 units. RESULTS: Of the 17,520 participants included in the final analysis, 72 (0.4%) developed early-onset, 251 (1.4%) preterm, and 420 (2.4%) term preeclampsia. Median gestational age at cell-free DNA measurement was 12.6 weeks, and 2155 (12.3%) had their cell-free DNA measurement at ≥16 weeks' gestation. Preeclampsia was associated with higher total cell-free DNA (median, 362.3 vs 339.0 copies/mL cell-free DNA; P<.001) and lower fetal fraction (median, 7.5% vs 9.4%; P<.001). The expected, cross-validated area under the curve scores for early-onset, preterm, and term preeclampsia were 0.782, 0.801, and 0.712, respectively, for the logistic regression model, and 0.797, 0.800, and 0.713, respectively, for the neural network model. At a screen-positive rate of 15%, sensitivity for preterm preeclampsia was 58.4% (95% confidence interval, 0.569-0.599) for the logistic regression model and 59.3% (95% confidence interval, 0.578-0.608) for the neural network model. The contribution of both total cell-free DNA and fetal fraction to the prediction of term and preterm preeclampsia was negligible. For early-onset preeclampsia, removal of the total cell-free DNA and fetal fraction features from the neural network model was associated with a 6.9% decrease in sensitivity at a 15% screen-positive rate, from 54.9% (95% confidence interval, 52.9-56.9) to 48.0% (95% confidence interval, 45.0-51.0). CONCLUSION: Routinely available patient characteristics and cell-free DNA markers can be used to predict preeclampsia with performance comparable to that of other patient characteristic models for the prediction of preterm preeclampsia. Logistic regression and neural network models showed similar performance.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Khalil A, Bellesia G, Norton ME, et al. The role of cell-free DNA biomarkers and patient data in the early prediction of preeclampsia: an artificial intelligence model. Am J Obstet Gynecol. 2024. PMID: 38432413. doi:10.1016/j.ajog.2024.02.299

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。